DiaPharma’s Human Serum Liver-FABP (FABP1) ELISA Kit is a sandwich-type ELISA kit, provided by DiaPharma Group, to be used for the in vitro quantitative determination of human L-FABP in serum, plasma, urine, and cell culture supernatant samples.  The kit is supplied in a standard 96-well format with 12 ready-to-use pre-coated 8-well removable strips.  All reagents including buffers and a native 2x Human L-FABP standard are also supplied with the kit.


Product Specifications:

Upper limit of detection:  25000 pg/mL

Lower limit of detection:  100 pg/mL

Sample volume:  100 uL

Antibodies:  Capture, Monoclonal  Detection, Monoclonal

Standard:  Native human protein

Assay time:  3.5 hours

Samples:  Serum, plasma, urine, cell culture supernatant

Format:  Standard ELISA

Cross Reactivity:  Human, Monkey, Swine




The Human Serum L-FABP ELISA Kit is for the quantitative determination of human L-FABP in serum, plasma, urine, and cell culture supernatant. L-FABP is a low molecular weight soluble protein (14kDa) expressed in the hepatocytes of the liver, the proximal tubule epithelium of the kidney, the aveolar epithelium of the lung, and enterocytes of the small intestine. Due to its small size, L-FABP leaks rapidly out of ischemically damaged necrotic cells, leading to a rise in serum levels. L-FABP is excreted into the urine following oxidative stress-induced injury of kidney tubules. L-FABP is an interesting biomarker to analyze during research of pathologic conditions of the kidney, heart, liver, and septic shock.


In the kidney, L-FABP is excreted in urine in response to ischemia (or low capillary blood flow) and oxidative stress on renal proximal tubules. This makes L-FABP useful as a biomarker for the early detection of renal disease accompanying tubular dysfunction. This is important to monitor while analyzing early stages of chronic kidney disease (CKD) and detecting diabetic nephropathy in type 2 diabetes. L-FABP has comparable discriminative capabilities to NGAL for detecting acute kidney injury (AKI) in adult populations, as described by a meta-analysis of 27 published studies analyzing urinary L-FABP levels in AKI prediction.


L-FABP is an important biomarker linked to cardiorenal syndrome, a complex association of the kidneys and heart following acute or chronic injury. Urinary L-FABP levels are higher in acute heart failure cases developing AKI than in those that are not developing AKI. Serum and urinary L-FABP function as a biomarker in clinical studies for predicting AKI following cardio-vascular surgery.  Plasma L-FABP levels are elevated following atrial fibrillation events suggesting that dysregulated fatty acid metabolism may be a contributor to atrial fibrillation.


In the liver, L-FABP is a sensitive marker of rapid hepatocyte lysis and shows superior characteristics regarding tissue distribution and kinetics compared to ALT. Serum L-FABP levels are elevated in non-alcoholic steatohepatitis (NASH) and have been shown to correlate with the degree of fibrosis and inflammation. L-FABP may aid as a non-invasive marker in determining the severity of fibrosis and inflammation in NASH research, transplantation research, as well as function as an early indicator of nonalcoholic fatty liver disease (NAFLD) and NASH. During drug induced liver injury (DILI) research, L-FABP has been recognized as a biomarker for safety testing. Levels of L-FABP in the urine are a promising prognostic biomarker of acute-on-chronic liver failure (ACLF) and mortality in patients with decompensated cirrhosis.

Septic Shock:

Elevated urinary L-FABP levels have been reported in individuals with septic shock, suggestive of renal tubular damage.